<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Clin Transl Sci</span><span class="iso-abbrev" title="iso-abbrev">Clin Transl Sci</span><span class="doi" title="doi">10.1111/(ISSN)1752-8062</span><span class="publisher-id" title="publisher-id">CTS</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Clinical and Translational Science</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1752-8054</span><span class="issn-epub" tagx="issn" title="issn-epub">1752-8062</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">John Wiley and Sons Inc.</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Hoboken</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7485949">7485949</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1111/cts.12816">10.1111/cts.12816</a></span><span class="publisher-id" title="publisher-id">CTS12816</span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Commentary</span><div class="sub-group" title="subj-group">
: <span class="subject" title="subject">Perspectives</span>: <span class="subject" title="subject">Commentaries</span></div> </div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVIDâ€�19</div> <div class="alt-title" title="alt-title">
Passive Immunotherapy for COVIDâ€�19</div> <div class="alt-title" title="alt-title">
Morabito and Gangadharan</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Morabito</span><span class="given-names" tagx="given-names" title="given-names">Christopher J.</span></span><a href="#cts12816-aff-0001"><sup>1</sup></a><span class="address" title="address"><span class="email" tagx="email" title="email">Christopher.morabito@takeda.com</span></span></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gangadharan</span><span class="given-names" tagx="given-names" title="given-names">Bagirath</span></span><a href="#cts12816-aff-0002"><sup>2</sup></a></span></div><span class="citation_author_institution" id="cts12816-aff-0001">[1], <span class="institution" title="institution">Millennium Pharmaceuticals, Inc, a Takeda company</span><span class="city" tagx="city" title="city">Cambridge</span><span class="named-content" title="named-content">Massachusetts</span><span class="country" tagx="country" title="country">USA</span></span><span class="citation_author_institution" id="cts12816-aff-0002">[2], <span class="institution" title="institution">Baxalta Innovations GmbH, a Takeda company</span><span class="city" tagx="city" title="city">Vienna</span><span class="country" tagx="country" title="country">Austria</span></span><div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">*</span> Correspondence: Christopher Morabito (<span class="email" tagx="email" title="email">Christopher.morabito@takeda.com</span>)<br /><br /></div> </div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-6-6</span></span><span class="pub-date-ppub" title="pub-date-ppub">ppub: <span>2020-9</span></span><span class="volume" tagx="volume" title="volume">13</span><span class="issue" tagx="issue" title="issue">5</span><span class="issue-id" tagx="issue-id" title="issue-id">10.1111/cts.v13.5</span><span class="fpage" tagx="fpage" title="fpage">835</span><span class="lpage" tagx="lpage" title="lpage">837</span><span class="history" title="history"><span class="received" title="received">received: 2020-4-30</span><span class="accepted" title="accepted">accepted: 2020-5-12</span></span><div class="permissions"><span class="copyright" title="copyright">(C) , </span><span class="license" title="license"><span class="license-p" title="license-p">This is an open access article under the terms of the <a href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</span></span></div><a class="self-uri" href="file:CTS-13-835.pdf" title="self-uri">file:CTS-13-835.pdf</a><div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> <div class="custom-meta-group" title="custom-meta-group"> <meta name="source-schema-version-number" value="2.0" /> <meta name="cover-date" value="September 2020" /> <meta name="details-of-publishers-convertor" value="Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.0 mode:remove_FC converted:11.09.2020" /> </div> </div> </div> <div class="body" title="body"> <p>Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the firstâ€�line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now coronavirus disease 2019 (COVIDâ€�19).<a href="#cts12816-bib-0001"><sup>1</sup></a> Over the last several decades, as technology has developed to purify and manufacture plasmaâ€�derived immunoglobulin (IgG) as a drug therapy, hyperimmune globulin (Hâ€�IG) formulations have been used as the secondâ€�line of passive immunotherapies against these diseases. Hâ€�IGs are preparations of immunoglobulins with known titers of neutralizing antibodies against specific infectious agents, such as rabies, hepatitis B, and cytomegalovirus.</p> <p>CP or Hâ€�IG treatments have demonstrated clinical benefits in previous coronavirus epidemics. In severe acute respiratory syndrome (SARS), caused by SARSâ€�coronavirus (CoV), highly homologous to SARSâ€�CoVâ€�2, CP or Hâ€�IG reduced mortality and hospital stay.<a href="#cts12816-bib-0002"><sup>2</sup></a> In a metaâ€�analysis involving 32 studies of SARS or severe influenza, passive immunotherapy lowers mortality, especially if administered early in disease (within 5Â days of symptoms). Yet, these studies often lacked control groups or had high risk of bias.<a href="#cts12816-bib-0003"><sup>3</sup></a></p> <p>COVIDâ€�19 is a historic pandemic that is testing populations, healthcare systems, and the biopharmaceutical industry in previously unimagined ways. We now are seeing new drug developers, including biopharmaceutical companies, government agencies, academicians, and private foundations, come together in full force to consider approaches to treat and prevent infection with SARSâ€�CoVâ€�2. Vaccines, which if effective will result in mass active immunity, are now in clinical trials. The most advanced vaccines (Moderna and Oxford/Astra Zeneca) could be available via emergency use authorization as early as Fall 2020. The first wave of therapies, such as remdesivir (Gilead), are completing clinical trials and the second wave, including repurposed existing drugs and new drug candidates, are now entering clinical trials. Until vaccines and new therapeutics are widely available, passive immunotherapies to manage COVIDâ€�19 may prove to be effective agents in the fight against SARSâ€�CoVâ€�2 and COVIDâ€�19.</p> <div class="passiveimmunityinthecontextofcovidâ€�19" title="sec"> <div class="title" tagx="title" title="title">
PASSIVE IMMUNITY IN THE CONTEXT OF COVIDâ€�19</div> <p>Passive immunity is conferred by the transfer of pathogenâ€�specific antibodies and, in the case of CP, innate humoral immune factors, to patients atâ€�risk of developing or actively suffering from infection. The pathogenâ€�specific antibodies include all immunoglobulin isotypes (IgG, IgM, IgA, and IgE) and nonspecified humoral innate immunity factors in CP or high purity polyclonal IgG and its subclasses in Hâ€�IG. In viral diseases, antibodies exert effect by viral neutralization (blocking viral cell entry and, therefore, replication), complement activation, opsonization, and antibodyâ€�dependent cellular cytotoxicity mediation. Viral neutralization is antigenâ€�specific; other antiviral activities are antigenâ€�nonspecific and are effected in part via Fc:FcReceptor interactions. In SARSâ€�CoVâ€�2 infection, the principle target antigen associated with neutralization is the Spike protein, which is responsible for SARSâ€�CoVâ€�2 attachment to epithelial cells, including pneumocytes. The antibodies in COVIDâ€�19 passive immunotherapies are polyclonal in nature, with multiple epitopes against SARSâ€�CoVâ€�2 paratopes, including the receptorâ€�binding domain in the Spike protein.</p> <p>Both CP and Hâ€�IG depend on plasma collected from patients who have recovered from the diseases. The US Food and Drug Administration (FDA) has provided nonbinding recommendations for CP donation: donors must have had documented infection with SARSâ€�CoVâ€�2 (realâ€�time polymerase chain reaction or serology) and at least 28Â days from resolution of symptoms or at least 14Â days without symptoms and a negative realâ€�time polymerase chain reaction test.<a href="#cts12816-bib-0004"><sup>4</sup></a></p> <p>CP has been used compassionately in this pandemic and is currently in clinical trials via an expanded access program in the United States, managed by the COVIDâ€�19 Convalescent Plasma Project (CCPP19.org). In a published report of 10 critically ill patients in China, 200Â mL of plasma with titers of at least 1:640 on top of supportive care improved signs and symptoms in critically ill patients.<a href="#cts12816-bib-0005"><sup>5</sup></a> Assuming an average normal level of IgG, 200Â mL equates to ~Â 2Â g of IgG, or 0.03Â g/kg in a 70Â kg adult. The process for using CP as a therapy is straightforward and efficient: one or two units of fresh, frozen, and virusâ€�inactivated plasma (~Â 250â€"500Â mL, or up to ~Â 5Â g of IgG) collected from individual convalescent patient(s) is administered to blood groupâ€�matched patients. Although CP is screened for neutralization titers, the titers are not standardized, and the dose of antibodies (including IgG) and other immune factors is unknown. The FDA recommends that CP neutralization titers are at least 1:160.<a href="#cts12816-bib-0004"><sup>4</sup></a></p> <p>Hâ€�IG is a drug derived from convalescent plasma. Hâ€�IG is produced following normal IG production processes, via a fractionation process that results in a purified mix of IgGs in subclass ratios that mimic human IgG subclass mixtures (in this case, to ratios in COVIDâ€�19 convalescent patients). The product will have a diverse set of polyclonal antibodies against SARSâ€�CoVâ€�2, with a standard, measured neutralization titer prior to release. The final product is finished to a precise concentration of IgG (10% solution is common). As a drug, Hâ€�IG is regulated by health authorities, and several biopharmaceutical companies with specific infrastructure to produce plasmaâ€�derived therapies have announced Hâ€�IG programs.</p> </div> <div class="hâ€�ighasthepotentialtobeasustainableimmunotherapy" title="sec"> <div class="title" tagx="title" title="title">
Hâ€�IG HAS THE POTENTIAL TO BE A SUSTAINABLE IMMUNOTHERAPY</div> <p>Manufacturing clinical and commercial supply of Hâ€�IG depends on plasma collection. In the United States, Europe, Japan, and China, there is established and highly regulated plasma collection infrastructure that is being mobilized now to collect plasma from the increasing number of convalescent patients in these regions. Once collected and pooled, plasma is manufactured into Hâ€�IG through a series of steps that can take several months: fractionation, purification, incubation, release testing, finishing, and packaging. The process ensures product purity, pathogen safety, and adequate titers of neutralizing antibodies before release for clinical use. Hâ€�IG may be stored up to 3Â years depending on conditions. Further, Hâ€�IGs may be manufactured at commercial scale, following the process outlined above, with manufacturing runs that can process up to 20,000Â L of plasma.</p> <p>The Hâ€�IG is expected to behave pharmacokinetically like IG (i.v.). <b>Table </b><a href="#cts12816-tbl-0001"><b>1</b></a> shows an example of pharmacokinetic (PK) characteristics for a commercially available IG (i.v.) product.<a href="#cts12816-bib-0006"><sup>6</sup></a> The short time of maximum plasma concentration (T<sub>max</sub>) and long T1â€�2 suggest that a single infusion of Hâ€�IG may be sufficient for treatment in the acute disease settings. In upcoming studies, it is important to confirm that the PK of SARSâ€�CoVâ€�2 specific antibodies administered therapeutically in an active disease state is similar the PK of IG (i.v.).</p> <div class="table-wrap_UNKNOWN" id="cts12816-tbl-0001" content-type="Table" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1</span> <p>Select pharmacokinetic parameters and estimates of IgG levels after infusion of a commercially available IVIG 10% (200â€"800Â mg/kg, mean dose 453Â mg/kg) at 4Â week intervals (Melamed <i>et al</i>.<a href="#cts12816-bib-0006"><sup>6</sup></a>)</p>  <table frame="hsides" rules="groups"> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <thead valign="top"> <tr style="border-bottom:solid 1px #000000"> <th align="left" valign="top" rowspan="1" colspan="1">Parameter</th> <th align="left" valign="top" rowspan="1" colspan="1">Median (min, max)</th> </tr> </thead> <tbody> <tr> <td align="left" rowspan="1" colspan="1">C<sub>min</sub>, g/L</td> <td align="left" rowspan="1" colspan="1">9 (6.8, 20.6)</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">C<sub>max</sub>, g/L</td> <td align="left" rowspan="1" colspan="1">16.5 (12.7, 26.0)</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">T<sub>max</sub>, hours</td> <td align="left" rowspan="1" colspan="1">2.5 (1.8, 26.3)</td> </tr> <tr> <td align="left" rowspan="1" colspan="1"><i>T</i><sub>1/2</sub>, days</td> <td align="left" rowspan="1" colspan="1">37.4 (18.7, 131.7)</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Vd, L/kg</td> <td align="left" rowspan="1" colspan="1">0.09 (0.0, 0.2)</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN" id="cts12816-ntgp-0001"> <div class="fn-type-" title=""> <p>C<sub>max</sub>, peak plasma concentration; C<sub>min</sub>, minimum plasma concentration; IgG, immunoglobulin; IVIG, intravenous immunoglobulin; T<sub>1/2</sub>, terminal halfâ€�life; T<sub>max</sub>, time to peak plasma concentration; Vd, volume of distribution.</p> </div> </div> <div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">John Wiley &amp;amp; Sons, Ltd</span>, </span></div> </div> <p>To assess PDs, animal models may be a key mainstay in COVIDâ€�19. Preclinical studies using human transgenic ACE2 mice and nonâ€�human primates will provide prospective understandings of minimal protective titers that can substantiate human dosing, evaluate efficacy in a therapeutic setting, and address key safety risks (as discussed below). Ongoing preclinical experiments can substantiate the proposed clinical dose through pharmacometric modeling of the PK/PD relationship. However, due to the urgency of the pandemic and the speed of clinical development in this situation, these experiments will run concurrently with pivotal clinical trials. Thus, the early reads on PD may come from human therapy trials.</p> <p>Although the clinical dose will be defined in clinical trials, <i>in vitro</i> neutralization titers of the finished product will inform dose selection. Based on assessments done in our own laboratories, the current estimate is that the dose will range from 0.1 to 0.5g/kg, given i.v. once (every 28Â days if used for prophylaxis). The experience to date with CP as therapy suggests that a lower dose may be effective: this will be tested in randomized clinical trials.</p> <p>To date, no highâ€�quality clinical trial has demonstrated convincing efficacy and safety of Hâ€�IG in coronavirus epidemics. Thus, randomized controlled trials are needed now to establish the benefitâ€�risk balance of this intervention for COVIDâ€�19 and to guide future Hâ€�IG use in new, emerging epidemics. Target indications for the COVIDâ€�19 Hâ€�IG include treatment and prevention. In coronavirus diseases, including COVIDâ€�19, endogenous antibody production is nondetectable early in disease (<div class="â_UNKNOWN" href="#cts12816-bib-0007"><sup>7</sup> Thus, patients who have rapidly progressing yet early disease may benefit from the antibody boost that would come from Hâ€�IG. Randomized, placebo controlled clinical trials in treatment paradigms are anticipated to begin in Summer 2020.</div></p> <p>In prevention, the initial targeted population could be preâ€�exposure prophylaxis in frontâ€�line healthcare providers (HCPs). To date, several hundred HCPs have died from COVIDâ€�19.<a href="#cts12816-bib-0008"><sup>8</sup></a> High infection rates in HCPs translate to direct and indirect harm: as the individual HCP is infected and suffers from the disease and is a potential fomite for new infection, additional HCPs are called in to care for patients and are at higher risk for infection.</p> </div> <div class="antibodyâ€�dependentenhancementandsafetyconcerns" title="sec"> <div class="title" tagx="title" title="title">
ANTIBODYâ€�DEPENDENT ENHANCEMENT AND SAFETY CONCERNS</div> <p>In general, i.v. IgG is wellâ€�tolerated and the safety profile is well known. Common adverse reactions are mild and selfâ€�limiting, but severe adverse effects, including thrombosis, renal dysfunction, and death, are known to occur in highâ€�risk patients. Little is known about the safety of CP or Hâ€�IGs when used to manage coronavirus infections. There is a theoretical concern that Hâ€�IG against coronavirus, including SARSâ€�CoVâ€�2, may potentiate disease via a mechanism called antibodyâ€�dependent enhancement (ADE), and earlier studies of Hâ€�IG in SARS and Middle East respiratory syndrome (MERS) have not provided enough information to extrapolate to COVIDâ€�19.</p> <p>ADE describes two basic phenomena mediated by virusâ€�specific antibodies: enhanced viral infection and enhanced immunologic response in the advanced disease, independent from viral load. There are no data to date to suggest that ADE occurs in COVIDâ€�19, but research in this space is relatively immature. The strongest set of data on ADE in coronavirus infections come from SARSâ€�CoV. <i>In vitro</i> data suggest that although antiâ€�Spike protein serum inhibits viral entry into epithelial cells incubating in SARSâ€�CoV inoculated medium, there is enhanced uptake of virus in immune cells via FcgammaRII (not ACE2)<a href="#cts12816-bib-0009"><sup>9</sup></a>: whether this uptake enhances immune pathology requires scientific evaluation. Additional <i>in vivo</i> results from a macaque model showed that induction of antiâ€�SARSâ€�CoV Spike IgG resulted in enhancedâ€�acute lung injury, related to enhanced proâ€�inflammatory morphological changes in alveolar macrophage.<a href="#cts12816-bib-0010"><sup>10</sup></a> Additional preclinical animal studies are needed to understand whether Hâ€�IGs at high neutralization titers will enhance antibodyâ€�dependent immune pathology. Human data to correlate these findings do not exist, yet, it is important to note that in SARS ~Â 80% of patients developed acute respiratory distress syndrome (ARDS), coincidentally with IgG seroconversion. Preclinical and clinical correlation in COVIDâ€�19 are needed.</p> </div> <div class="passiveimmunotherapyasaplatformforthisandfutureepidemics" title="sec"> <div class="title" tagx="title" title="title">
PASSIVE IMMUNOTHERAPY AS A PLATFORM FOR THIS AND FUTURE EPIDEMICS</div> <p>Passive immunotherapy from convalescent plasma and Hâ€�IG drugs may be effective in future epidemics caused by novel or known pathogens, to target pathogens against which no existing direct antiviral therapy exists. These approaches may be standardized and scaled, and we are actively learning how to initiate collections, supply, clinical trials, and distribution network in order to mobilize agilely for the next epidemic. As Hâ€�IG therapies become available, rapid and costâ€�effective distribution needs to be ensured to optimize the full potential of this therapy.</p> </div> <div class="funding" title="sec"> <div class="title" tagx="title" title="title">
Funding</div> <p>No funding was received for this work.</p> </div> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Conflict of Interest</div> <p>C.J.M. is a fullâ€�time employee of Takeda Pharmaceuticals. B.G. is a fullâ€�time employee of Takeda Pharmaceuticals. Takeda Pharmaceuticals is involved in developing a Covidâ€�19 hyperimmune globulin (Hâ€�IG), part of the CoVIgâ€�19 Plasma Alliance.</p> </div> <div class="disclosures" title="sec"> <div class="title" tagx="title" title="title">
Disclosures</div> <p>B.G.: Employee of Baxalta Innovations, a member of the Takeda group of companies, Vienna, Austria; holds stock options of Takeda C.J.M. Millennium Pharmaceuticals, Inc, a Takeda company, holds stock options of Takeda.</p> </div> </div> <div class="back" title="back"> <div class="references">
References</div> <div tag="ref-list"> <ul> <li tag="ref"><a name="cts12816-bib-0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bloch</span>, <span class="given-names" tagx="given-names" title="given-names">E.M.</span></span><i>et al.</i><span class="mixed-article-title" title="mixed-article-title">Deployment of convalescent plasma for the prevention and treatment of COVIDâ€�19</span>. <span class="source" tagx="source" title="source">J. Clin. Invest</span> (<span class="year" tagx="year" title="year">2020</span>). <span class="pub-id"><a href="https://dx.doi.org/10.1172/JCI138745">10.1172/JCI138745</a></span></span></li> <li tag="ref"><a name="cts12816-bib-0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lai</span>, <span class="given-names" tagx="given-names" title="given-names">S.T.</span></span><span class="mixed-article-title" title="mixed-article-title">Treatment of severe acute respiratory syndrome</span>. <span class="source" tagx="source" title="source">Eur. J. Clin. Microbiol. Dis.</span><span class="volume" tagx="volume" title="volume">24</span>, <span class="fpage" tagx="fpage" title="fpage">583</span>â€"<span class="lpage" tagx="lpage" title="lpage">591</span> (<span class="year" tagx="year" title="year">2005</span>).</span></li> <li tag="ref"><a name="cts12816-bib-0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mairâ€�Jenkin</span>, <span class="given-names" tagx="given-names" title="given-names">J.</span></span><i>et al.</i><span class="mixed-article-title" title="mixed-article-title">The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systemic review and exploratory metaâ€�analysis</span>. <span class="source" tagx="source" title="source">J. Infect. Dis.</span><span class="volume" tagx="volume" title="volume">211</span>, <span class="fpage" tagx="fpage" title="fpage">80</span>â€"<span class="lpage" tagx="lpage" title="lpage">90</span> (<span class="year" tagx="year" title="year">2015</span>).<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25030060">25030060</a></span></span></li> <li tag="ref"><a name="cts12816-bib-0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: US Food and Drug Administration (FDA)</span> . <span class="mixed-article-title" title="mixed-article-title">Recommendations for Investigational COVIDâ€�19 Convalescent Plasma</span>. &amp;lt;<a href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma">https://www.fda.gov/vaccinesâ€�bloodâ€�biologics/investigationalâ€�newâ€�drugâ€�indâ€�orâ€�deviceâ€�exemptionâ€�ideâ€�processâ€�cber/recommendationsâ€�investigationalâ€�covidâ€�19â€�convalescentâ€�plasma</a>&amp;gt; (<span class="year" tagx="year" title="year">2020</span>). Accessed April 30, 2020.</span></li> <li tag="ref"><a name="cts12816-bib-0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Duan</span>, <span class="given-names" tagx="given-names" title="given-names">K.</span></span><i>et al.</i><span class="mixed-article-title" title="mixed-article-title">Effectiveness of convalescent plasma therapy in severe COVIDâ€�19 patients</span>. <span class="source" tagx="source" title="source">Proc. Natl. Acad. Sci. USA</span><span class="volume" tagx="volume" title="volume">117</span>, <span class="fpage" tagx="fpage" title="fpage">9490</span>â€"<span class="lpage" tagx="lpage" title="lpage">9496</span> (<span class="year" tagx="year" title="year">2020</span>).<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32253318">32253318</a></span></span></li> <li tag="ref"><a name="cts12816-bib-0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Melamed</span>, <span class="given-names" tagx="given-names" title="given-names">J.R.</span></span><i>et al.</i><span class="mixed-article-title" title="mixed-article-title">Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: analysis of a phase III, multicenter, prospective, openâ€�label study</span>. <span class="source" tagx="source" title="source">Eur. J. Pharm. Sci.</span><span class="volume" tagx="volume" title="volume">118</span>, <span class="fpage" tagx="fpage" title="fpage">80</span>â€"<span class="lpage" tagx="lpage" title="lpage">86</span> (<span class="year" tagx="year" title="year">2018</span>).<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29522908">29522908</a></span></span></li> <li tag="ref"><a name="cts12816-bib-0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Long</span>, <span class="given-names" tagx="given-names" title="given-names">Q.â€�X.</span></span><i>et al.</i><span class="mixed-article-title" title="mixed-article-title">Antibody response to SARSâ€�CoVâ€�2 in patients with COVIDâ€�19</span>. <span class="source" tagx="source" title="source">Nat. Med.</span> (<span class="year" tagx="year" title="year">2020</span>). <span class="pub-id"><a href="https://dx.doi.org/10.1038/s41591-020-0897-1">10.1038/s41591-020-0897-1</a></span></span></li> <li tag="ref"><a name="cts12816-bib-0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: Medscape</span> . <span class="mixed-article-title" title="mixed-article-title">In memoriam: healthcare workers who have died of Covidâ€�19</span>. &amp;lt;<a href="https://www.medscape.com/viewarticle/927976">https://www.medscape.com/viewarticle/927976</a>&amp;gt; (<span class="year" tagx="year" title="year">2020</span>). Accessed April 30, 2020.</span></li> <li tag="ref"><a name="cts12816-bib-0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Jaume</span>, <span class="given-names" tagx="given-names" title="given-names">M.</span></span><i>et al.</i><span class="mixed-article-title" title="mixed-article-title">Antiâ€�severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pHâ€� and cysteine proteaseâ€�independent FcgammaR pathway</span>. <span class="source" tagx="source" title="source">J. Virol.</span><span class="volume" tagx="volume" title="volume">85</span>, <span class="fpage" tagx="fpage" title="fpage">10582</span>â€"<span class="lpage" tagx="lpage" title="lpage">10597</span> (<span class="year" tagx="year" title="year">2011</span>).<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21775467">21775467</a></span></span></li> <li tag="ref"><a name="cts12816-bib-0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Liu</span>, <span class="given-names" tagx="given-names" title="given-names">L.</span></span><i>et al.</i><span class="mixed-article-title" title="mixed-article-title">Antiâ€�spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARSâ€�CoV infection</span>. <span class="source" tagx="source" title="source">JCI Insight</span><span class="volume" tagx="volume" title="volume">4</span>, pii: 123158 (<span class="year" tagx="year" title="year">2019</span>).</span></li> </ul> </div> </div>  </body></html>